A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation
Phase of Trial: Phase III
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
- 25 Oct 2017 According to a Vertex Pharmaceuticals media release, enrollment is complete in the 12 to 24 months age group in this trial.
- 11 Sep 2017 New trial record
- 10 Sep 2017 Planned End Date changed from 4 Jun 2021 to 7 Jun 2021.